SAB Biotherapeutics, Inc. (SABSW) stock
Close on Oct 20, 2026Market cap $304.80MP/E –Yield –
SAB Biotherapeutics, Inc. saw revenue fall 100.0% to $0 over fiscal 2025. Free cash flow was -$45.71M. At the latest close the market valued the company at $304.80M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $304.80M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.42
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $0
- Net income
- -$12.78M
- EPS, diluted
- -$0.79
- Free cash flow
- -$45.71M
- Book value per share
- $2.69
- Diluted shares
- 80M
Trading
- Previous close
- $0.01
- Open
- $0.01
- Volume
- 16,902
- Average volume (20 days)
- 38,795
- Beta (5 years)
- 1.41
- 52-week range
- $2.44 – $5.15
- RSI (14 days)
- 60.2
- Volatility (1 year)
- 61.4%
- Relative volume
- 1.27×
- WACC
- 12.0%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 20, 2026. The S&P 500 is measured by the SPY fund.
| Period | SABSW | S&P 500 | Difference | SABSW per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -28.6% | +1.0% | −29.5 pts | ||
| 3 months | -42.2% | +3.9% | −46.1 pts | ||
| Year to date | -67.9% | +13.7% | −81.6 pts | ||
| 1 year | -66.2% | +15.8% | −82.0 pts | ||
| 3 years | -87.5% | +89.3% | −176.8 pts | -50.0% | +23.7% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases SAB Biotherapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Update
- Update
- Update
- News
- News
About SAB Biotherapeutics
Biological Products, (No Diagnostic Substances)
The company is a clinical-stage biopharmaceutical firm that develops human immunoglobulin G antibodies to treat and prevent immune and autoimmune disorders. It utilizes a specialized production platform involving genetically engineered cattle to generate human polyclonal antibodies without requiring human blood donors. Its primary drug candidate is SAB-142, an immunotherapy designed to protect insulin-producing pancreatic beta cells and slow the progression of type 1 diabetes. The company's therapies are intended for patients suffering from autoimmune conditions, specifically pediatric, adolescent, and adult individuals diagnosed with type 1 diabetes.
Company profile, executives and historySAB Biotherapeutics stock: common questions
What is SAB Biotherapeutics's stock price?
SABSW closed at $0.01 on Oct 20, 2026, up 33.33% on the day. Over the past 52 weeks it traded between $2.44 and $5.15.
What is SAB Biotherapeutics's market cap?
SAB Biotherapeutics was worth $304.80M at the close on Oct 20, 2026: the share price times the diluted shares outstanding.
What is SABSW's P/E ratio?
SAB Biotherapeutics lost money over fiscal 2025 (diluted EPS -$0.79), so it has no meaningful P/E ratio.
How much revenue does SAB Biotherapeutics make?
SAB Biotherapeutics reported revenue of $0 for fiscal 2025, down 100.0% from a year earlier.
Does SAB Biotherapeutics pay a dividend?
No. SAB Biotherapeutics has not paid a cash dividend over the last twelve months.
How has SABSW stock performed over the past year?
Including dividends, SABSW returned -66.2% over the past year, against +15.8% for the S&P 500.
Who are SAB Biotherapeutics's competitors?
Companies most similar to SAB Biotherapeutics by business, industry and size include SCNI, IMA, PLUR, INBX, PROK.